

# James W Janetka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7127724/publications.pdf>

Version: 2024-02-01

65  
papers

3,772  
citations

136950

32  
h-index

128289

60  
g-index

85  
all docs

85  
docs citations

85  
times ranked

5115  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aspartyl Protease Inhibitors as Anti-Filarial Drugs. <i>Pathogens</i> , 2022, 11, 707.	2.8	4
2	Novel approaches to glycomimetic design: development of small molecular weight lectin antagonists. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 513-536.	5.0	5
3	A host receptor enables type 1 pilus-mediated pathogenesis of <i>Escherichia coli</i> pyelonephritis. <i>PLoS Pathogens</i> , 2021, 17, e1009314.	4.7	19
4	An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease. <i>Pathogens</i> , 2021, 10, 71.	2.8	16
5	A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	54
6	Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 18158-18174.	6.4	8
7	Heteroaryl amide smoothed inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2-pyridylmethoxy)benzamide (AZD7254). <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115227.	3.0	0
8	Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6144-6163.	6.4	14
9	Abstract 3451: Non-genetic RTK-mediated cetuximab resistance in colorectal cancer offers multiple targets for therapeutic intervention. , 2020, , .		3
10	Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics. <i>Scientific Reports</i> , 2019, 9, 9085.	3.3	25
11	Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. <i>MedChemComm</i> , 2019, 10, 1646-1655.	3.4	8
12	Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2. <i>Future Medicinal Chemistry</i> , 2019, 11, 743-769.	2.3	14
13	Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 480-490.	6.4	22
14	Hepatocyte growth factor activator inhibitor-2 stabilizes Epcam and maintains epithelial organization in the mouse intestine. <i>Communications Biology</i> , 2019, 2, 11.	4.4	21
15	Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic <i>E. coli</i> (UPEC): Optimization through Iterative Rational Drug Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 467-479.	6.4	18
16	Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2819-E2828.	7.1	63
17	Precision antimicrobial therapeutics: the path of least resistance?. <i>Npj Biofilms and Microbiomes</i> , 2018, 4, 4.	6.4	69
18	MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. <i>Science</i> , 2018, 360, 336-341.	12.6	187

#	ARTICLE	IF	CITATIONS
19	Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1061-1073.	6.4	19
20	Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics. <i>ACS Infectious Diseases</i> , 2018, 4, 1130-1145.	3.8	18
21	Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins. <i>Analytical Chemistry</i> , 2017, 89, 2636-2644.	6.5	20
22	Evolutionary fine-tuning of conformational ensembles in FimH during host-pathogen interactions. <i>Science Advances</i> , 2017, 3, e1601944.	10.3	50
23	Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1. <i>Journal of Biological Chemistry</i> , 2017, 292, 9294-9304.	3.4	54
24	Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 711-731.	5.0	71
25	Selective depletion of uropathogenic <i>E. coli</i> from the gut by a FimH antagonist. <i>Nature</i> , 2017, 546, 528-532.	27.8	231
26	Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by <i>Toxoplasma gondii</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9976-9989.	6.4	57
27	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. <i>Cancers</i> , 2017, 9, 35.	3.7	85
28	Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. <i>Oncotarget</i> , 2017, 8, 63014-63025.	1.8	27
29	DDIS-10. TARGETING HGF/MET IN GBM BY RESTORING SPINT2 FUNCTION. <i>Neuro-Oncology</i> , 2016, 18, vi49-vi49.	1.2	0
30	Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. <i>ChemMedChem</i> , 2016, 11, 367-373.	3.2	53
31	1,4-Dithiazolo[5,4-c]quinoline Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/ROK Kinase Pathway Signaling in Cancer. <i>ChemMedChem</i> , 2016, 11, 585-599.	3.2	32
32	Carbohydrate Glycosides, Array-based Addressable Libraries, and the Versatility of Constant Current Electrochemistry. <i>Electroanalysis</i> , 2016, 28, 2808-2817.	2.9	3
33	Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 9390-9408.	6.4	84
34	Characterization of parasite-specific indels and their proposed relevance for selective anthelmintic drug targeting. <i>Infection, Genetics and Evolution</i> , 2016, 39, 201-211.	2.3	7
35	Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 175-197.	5.0	47
36	Identification of Small Molecule Inhibitors That Block the <i>Toxoplasma gondii</i> Rhopty Kinase ROP18. <i>ACS Infectious Diseases</i> , 2016, 2, 194-206.	3.8	20

#	ARTICLE	IF	CITATIONS
37	Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2328-2343.	3.0	31
38	Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic <i>Escherichia coli</i> . <i>MBio</i> , 2015, 6, e00820.	4.1	58
39	Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 1219-1224.	2.8	41
40	Abstract 2523: Mechanism-based inhibitors of HGFA, matriptase and hepsin for breast cancer treatment. , 2014, , .		0
41	A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic <i>Escherichia coli</i> ST131. <i>Journal of Infectious Diseases</i> , 2013, 208, 921-928.	4.0	116
42	Distinguishing the Contribution of Type 1 Pili from That of Other QseB-Misregulated Factors when QseC Is Absent during Urinary Tract Infection. <i>Infection and Immunity</i> , 2012, 80, 2826-2834.	2.2	35
43	Combinatorial Small-Molecule Therapy Prevents Uropathogenic <i>Escherichia coli</i> Catheter-Associated Urinary Tract Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4738-4745.	3.2	94
44	Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3945-3959.	6.4	112
45	Discovery of Checkpoint Kinase Inhibitor (<i>S</i>-5-(3-Fluorophenyl)-<i>N</i>-(-piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by Structure-Based Design and Optimization of Thiophenecarboxamide Ureas. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5130-5142.	6.4	58
46	Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4907-4911.	2.2	20
47	Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. <i>Trends in Molecular Medicine</i> , 2011, 17, 88-96.	6.7	240
48	Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors. <i>Science Translational Medicine</i> , 2011, 3, 109ra115.	12.4	254
49	Abstract LB-197: Hepatocyte Growth Factor Activator (HGFA) Inhibitors of c-MET/RON Kinase Signaling. , 2011, , .		0
50	Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4779-4792.	6.4	220
51	Discovery of a novel class of triazolones as Checkpoint Kinase inhibitorsâ€”Hit to lead exploration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5133-5138.	2.2	14
52	Checkpoint kinase inhibitors: a review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 165-197.	5.0	38
53	Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6362-6368.	6.4	133
54	Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4242-4248.	2.2	31

#	ARTICLE	IF	CITATIONS
55	Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1331-1340.	4.1	62
56	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2955-2966.	4.1	364
57	Flipped Out: Structure-Guided Design of Selective Pyrazolopyrrole ERK Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1280-1287.	6.4	108
58	Inhibitors of checkpoint kinases: from discovery to the clinic. <i>Current Opinion in Drug Discovery &amp; Development</i> , 2007, 10, 473-86.	1.9	23
59	Diaryldimethylpiperazine ligands with $\mu$ - and $\delta$ -opioid receptor affinity: Synthesis of (+)-4-[(1 $\pm$ R)-1-(4-allyl-(2S,5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N-phenylbenzamide <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 4761-4768.	3.0	5
60	Enantioconvergent Synthesis of ( $\alpha$ )-(2R,5S)-1-Allyl-2,5-dimethylpiperazine, an Intermediate to $\delta$ -Opioid Receptor Ligands. <i>Journal of Organic Chemistry</i> , 2003, 68, 3976-3980.	3.2	8
61	L-Selectride as a General Reagent for the O-Demethylation and N-Decarbomethoxylation of Opium Alkaloids and Derivatives. <i>Journal of Organic Chemistry</i> , 1998, 63, 4392-4396.	3.2	47
62	Novel Cyclic Biphenyl Ether Peptide $\beta$ -Strand Mimetics and HIV-Protease Inhibitors. <i>Journal of the American Chemical Society</i> , 1997, 119, 441-442.	13.7	59
63	Total Synthesis of the Cyclic Biphenyl Ether Peptides K-13 and OF4949-III via SNAr Macrocyclization of Peptidyl Ruthenium $\pi$ -Arene Complexes. <i>Journal of the American Chemical Society</i> , 1997, 119, 6488-6495.	13.7	83
64	A Cyclic Side-Chain-Linked Biphenyl Ether Tripeptide: H <sub>3</sub> N <sup>+</sup> -cyclo-[Phe(4 $\alpha$ 'O)-Phe-Phe(3 $\alpha$ 'O)]-OMe.Cl $\alpha$ '. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 1996, 52, 3112-3114.	0.4	12
65	Synthesis of peptidyl ruthenium $\pi$ -arene complexes: application to the synthesis of cyclic biphenyl ether peptides. <i>Journal of the American Chemical Society</i> , 1995, 117, 10585-10586.	13.7	66